Apis Capital Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Apis Capital Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-120,000	Closed	-$545K	–	50
2021 Q1	$545K	Hold	120,000	–	–	0.5%	36
2020 Q4	$689K	Buy	+120,000	New	+$908K	0.67%	32
2019 Q2	–	Sell	-110,000	Closed	-$1.46M	–	38
2019 Q1	$1.46M	Sell	110,000 -50,000	-31%	-$532K	1.76%	13
2018 Q4	$1.26M	Buy	+160,000	New	+$1.52M	1.69%	16

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Apis Capital Advisors's CBAY Position: Q2 2021 in Review

Apis Capital Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2021, closing a stake of 120,000 shares — an estimated $545K sold.

Apis Capital Advisors first reported a position in CBAY in Q4 2018 and held it in 4 quarters. The position peaked at $1.46M in Q1 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

Apis Capital Advisors reported no remaining Cymabay Therapeutics position as of Q2 2021 after selling out during the quarter.
Apis Capital Advisors sold 120,000 Cymabay Therapeutics shares in Q2 2021, an estimated $545K.
Apis Capital Advisors first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 4 quarters.
Apis Capital Advisors's Cymabay Therapeutics position peaked at $1.46M in Q1 2019.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on Apis Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.